NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
POCI
Precision Optics Corporation, Inc.
There isn't enough reported data to score POCI yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
POCI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Weak |
POCI's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
POCI PE Valuation
POCI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
POCI Forward outlook
There aren't enough analyst estimates for POCI to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over POCI on earnings quality, reporting a profit while its opponent remains loss making.
POCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$0.64 | +$0.25 |
| Q4 2025 | -$0.93 | -$0.29 |
| Q3 2025 | -$0.85 | -$0.23 |
| Q2 2025 | -$0.85 | -$0.36 |
| Q1 2025 | -$0.89 | -$0.61 |
| Q4 2024 | -$0.64 | -$0.34 |
| Q3 2024 | -$0.62 | -$0.56 |
| Q2 2024 | -$0.49 | -2550% |
POCI lost $0.64 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over POCI on profitability, with a higher operating margin.
POCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.8M | +42% |
| Q1 2026 | $8.7M | +108% |
| Q4 2025 | $7.4M | +63% |
| Q3 2025 | $6.7M | +59% |
| Q2 2025 | $6.2M | +31% |
| Q1 2025 | $4.2M | -20% |
| Q4 2024 | $4.5M | -6.2% |
| Q3 2024 | $4.2M | -2.9% |
POCI's revenue has grown year over year for five quarters in a row: $9M last quarter, up 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1.2% | +21 points |
| Q1 2026 | -0.7% | +48 points |
| Q4 2025 | -24% | -3.5 points |
| Q3 2025 | -24% | +5.8 points |
| Q2 2025 | -22% | +6.8 points |
| Q1 2025 | -49% | -44 points |
| Q4 2024 | -20% | -5.5 points |
| Q3 2024 | -30% | -20 points |
POCI's operating margin was −1.2% last quarter, up 21 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over POCI on cash generation, producing positive trailing cash flow while its opponent burns cash.
POCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$723.3K | +$1.3M |
| Q4 2025 | -$256.1K | +$560.6K |
| Q3 2025 | $78.2K | +$421.2K |
| Q2 2025 | -$615.5K | +$372.2K |
| Q1 2025 | -$2M | -$1.7M |
| Q4 2024 | -$816.6K | -$575.3K |
| Q3 2024 | -$343K | +$1.1M |
| Q2 2024 | -$987.6K | -$395.8K |
POCI has burned cash in most quarters: −$2M over the past year, against −$4M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over POCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
POCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +79.5K shares |
| 1 year | +13% | +877K shares |
| 3 years | +38% | +2.2M shares |
| 5 years | +66% | +3.1M shares |
| Available history | +82% | +3.5M shares |
POCI has 8M diluted shares, up 13% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
POCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | 4.6x | High |
POCI's net debt is about 4.6 years of its operating earnings (EBITDA).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
POCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.5 | Neutral |
| Stochastic | 69.4 | Neutral |
POCI's weekly RSI is 59 (neutral) and its Stochastic is 69 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
POCI PE vs Healthcare Sector
| Metric | POCI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
POCI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
POCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 8.5% above |
| 20 week MA | $4.53 | 10% above |
| 50 week MA | $4.60 | 8.7% above |
| 100 week MA | $4.59 | 8.9% above |
| 200 week MA | $5.26 | 4.9% below |
POCI has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
POCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.40 | $4.20 | -22% |
| 2021 | $4.20 | $7.20 | +71% |
| 2022 | $7.20 | $5.55 | -23% |
| 2023 | $5.55 | $6.02 | +8.5% |
| 2024 | $6.02 | $5.01 | -17% |
| 2025 | $5.01 | $4.21 | -16% |
| 2026 YTD | $4.21 | $5.00 | +19% |
POCI has the edge over NVO on returns for 2026, with the stronger performance.